TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone

Molecular and Cellular Biology

Volumn 26, Issue 20, 2006, Pages 7632-7644

  Gizard, Florence ^a,b,c   Robillard, Romain ^a,b,c   Gross, Barbara ^a,b,c   Barbier, Olivier ^a,b,c   Révillion, Françoise ^d   Peyrat, Jean Philippe ^d   Torpier, Gérard ^a,b,c   Hum, Dean W ^e   Staels, Bart ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e Parc Eurasante Lille Metropole   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN; RETINOBLASTOMA PROTEIN; SEX HORMONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TRANSCRIPTIONAL REGULATING FACTOR 132; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VACUOLE; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; HORMONAL REGULATION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; KNOCKOUT GENE; LIPID STORAGE; LIPID VACUOLE; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PREGNANCY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STEROIDOGENESIS;

BINDING SITES; BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGESTERONE; PROMOTER REGIONS (GENETICS); RECEPTORS, PROGESTERONE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 33749590570     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00326-06     Document Type: Article

References (72)

1. Achuthan, R., S. M. Bell, P. Roberts, J. P. Leek, K. Morgan, A. F. Markham, K. A. MacLennan, and V. Speirs. 2001. Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drugresistant clone. Cancer Genet. Cytogenet. 130:166-172.
2. Adams, P. D., X. Li, W. R. Sellers, K. B. Baker, X. Leng, J. W. Harper, Y. Taya, and W. G. Kaelin, Jr. 1999. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-CDK complexes. Mol. Cell. Biol. 19:1068-1080.
3. Alkhalaf, M., A. El-Mowafy, and S. Karam. 2002. Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein. Eur. J. Cancer Prev. 11:481-488.
4. Kipl and hormone dependence in breast cancer. Clin. Cancer Res. 10:368S-371S.
5. Balbin, M., and C. Lopez-Otin. 1996. Hormonal regulation of the human pepsinogen C gene in breast cancer cells. Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone. J. Biol. Chem. 271:15175-15181.
6. Beral, V. 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427.
7. Castro-Rivera, E., I. Samudio, and S. Safe. 2001. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem. 276:30853-30861.
8. Kipl protein: prognostic implications in primary breast cancer. Nat. Med. 3:227-230.
9. Chalbos, D., C. Joyeux, F. Galtier, and H. Rochefort. 1992. Progestin-induced fatty acid synthetase in human mammary tumors: from molecular to clinical studies. J. Steroid Biochem. Mol. Biol. 43:223-228.
10. Chwalisz, K., M. C. Perez, D. Demanno, C. Winkel, G. Schubert, and W. Elger. 2005. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and cndometriosis. Endocr. Rev. 26: 423-438.
11. Conneely, O. M., B. Mulac-Jericevic, and J. P. Lydon. 2003. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 68:771-778.
12. Cui, X., R. Schiff, G. Arpino, C. K. Osborne, and A. V. Lee. 2005. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23:7721-7735.
13. Datto, M. B., Y. Yu, and X. F. Wang. 1995. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 270:28623-28628.
14. Dib, C., S. Faure, C. Fizames, D. Samson, N. Drouot, A. Vignal, P. Millasseau, S. Marc, J. Hazan, E. Seboun, M. Lathrop, G. Gyapay, J. Morissette, and J. Weissenbach. 1996. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 380:152-154.
15. Di Lorenzo, D., M. Gianni, G. F. Savoldi, F. Ferrari, A. Albertini, and E. Garattini. 1993. Progesterone induced expression of alkaline phosphatase is associated with a secretory phenotype in T47D breast cancer cells. Biochem. Biophys. Res. Commun. 192:1066-1072.
16. Di Lorenzo, D., A. Albertini, and D. Zava. 1991. Progestin regulation of alkaline phosphatase in the human breast cancer cell line T47D. Cancer Res. 51:4470-4475.
17. Eden, J. 2003. Progestins and breast cancer. Am. J. Obstet. Gynecol. 188: 1123-1131.
18. Ekholm, S. V., and S. I. Reed. 2000. Regulation of G, cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 12:676-684.
19. Elstner, E., C. Muller, K. Koshizuka, E. A. Williamson, D. Park, H. Asou, P. Shintaku, J. W. Said, D. Heber, and H. P. Koeffler. 1998. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA 95:8806-8811.
20. Fabian, C. J., and B. F. Kimler. 2005. Selective estrogen-receptor modulators for primary prevention of breast cancer. J. Clin. Oncol. 23:1644-1655.
21. Gizard, F., M. El-Alfy, Y. Duguay, B. Lavallee, F. DeWitte, B. Staels, B. G. Beatty, and D. W. Hum. 2002. Function of the transcriptional regulating protein of 132 kDa (TReP-132) on human P450scc gene expression. Endocr. Res. 28:559-574.
22. Gizard, F., B. Lavallee, F. DeWitte, and D. W. Hum. 2001. A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression. J. Biol. Chem. 276:33881-33892.
23. Gizard, F., B. Lavallee, F. DeWitte, E. Teissier, B. Staels, and D. W. Hum. 2002. The transcriptional regulating protein of 132 kDa (TReP-132) enhances P450scc gene transcription through interaction with steroidogenic factor-1 in human adrenal cells. J. Biol. Chem. 277:39144-39155.
24. Kip1 Mol. Cell. Biol. 25:4335-4348.
25. Kipl gene. FEES Lett. 579:5535-5541.
26. Gizard, F., E. Teissier, I. Dufort, G. Luc, V. Luu-The, B. Staels, and D. W. Hum. 2004. The transcriptional regulating protein of 132 kDa (TReP-132) differentially influences steroidogenic pathways in human adrenal NC1-H295 cells. J. Mol. Endocrinol. 32:557-569.
27. Graham, J. D., and C. L. Clarke. 1997. Physiological action of progesterone in target tissues. Endocr. Rev. 18:502-519.
28. Kipl. Mol. Endocrinol. 11:1593-1607.
29. Guiochon-Mantel, A., and E. Milgrom. 1999. Role of progestins and progesterone receptors in breast cancer biology, p. 245-259. In A. Manni (ed.), Contemporary endocrinology: endocrinology of breast cancer. Humana Press Inc., Totowa, N.J.
30. Heery, D. M., E. Kalkhoven, S. Hoare, and M. G. Parker. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736.
31. Hong, J., I. Samudio, S. Liu, M. Abdelrahim, and S. Safe. 2004. Peroxisome proliferator-activated receptor gamma-dependent activation of p21 in Pane-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 145:5774-5785.
32. Horwitz, K. B., W. L. McGuire, O. H. Pearson, and A. Segaloff. 1975. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189:726-727.
33. 27Kip1 expression by vitamin D3. Oncogene 23:4856-4861.
34. Kip1 gene promoter that lacks vitamin D response elements. J. Biol. Chem. 274:32309-32317.
35. Joyeux, C., H. Rochefort, and D. Chalbos. 1989. Progestin increases gene transcription and messenger ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol. Endocrinol. 3:681-686.
36. Kenemans, P., and A. Bosman. 2003. Breast cancer and post-menopausal hormone therapy. Best Pract. Res. Clin. Endocrinol. Metab. 17:123-137.
37. Rester, H. A., B. M. van der Leede, P. T. van der Saag, and B. van der Burg. 1997. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J. Biol. Chem. 272:16637-16643.
38. Lacroix, M., and G. Leclercq. 2004. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83:249-289.
39. Lange, C. A., J. K. Richer, and K. B. Horwitz. 1999. Hypothesis: progester-one primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol. Endocrinol. 13:829-836.
40. Lee, E. Y., H. To, J. Y. Shew, R. Bookstein, P. Scully, and W. H. Lee. 1988. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218-221.
41. Kipl by tamoxifen. Biochem. Pharmacol. 66:371-377.
42. Lin, V. C., A. S. Eng, N. E. Hen, E. H. Ng, and S. H. Chowdhury. 2001. Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin. Cancer Res. 7:2880-2886.
43. Lin, V. C., R. Jin, P. H. Tan, S. E. Aw, C. T. Woon, and B. H. Bay. 2003. Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am. J. Pathol. 162:1781-1787.
44. Liu, Z., J. Wong, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 2001. Sequential recruitment of steroid receptor coactivator-1 (SRC-1) and p300 enhances progesterone receptor-dependent initiation and reinitiation of transcription from chromatin. Proc. Natl. Acad. Sci. USA 98:12426-12431.
45. Lydon, J. P., F. J. DeMayo, C. R. Funk, S. K. Mani, A. R. Hughes, C. A. Montgomery, Jr., G. Shyamala, O. M. Conneely, and B. W. O'Malley. 1995. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9:2265-2278.
46. Michna, H., Y. Nishino, G. Neef, W. L. McGuire, and M. R. Schneider. 1992. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J. Steroid Biochem. Mol. Biol. 41:339-348.
47. Mommers, E. C., A. M. Leonhart, F. Falix, R. Michalides, C. J. Meijer, J. P. Baak, and P. J. Diest. 2001. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J. Pathol. 194:327-333.
48. Mueller, E., P. Sarraf, P. Tontonoz, R. M. Evans, K. J. Martin, M. Zhang, C. Fletcher, S. Singer, and B. M. Spiegelman. 1998. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1:465-470.
49. Musgrove, E. A., and R. L. Sutherland. 1994. Cell cycle control by steroid hormones. Semin. Cancer Biol. 5:381-389.
50. Musgrove, E. A., A. Swarbrick, C. S. Lee, A. L. Cornish, and R. L. Sutherland. 1998. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18:1812-1825.
51. Neville, M. C., T. B. McFadden, and I. Forsyth. 2002. Hormonal regulation of mammary differentiation and milk secretion. J. Mammary Gland Biol. Neoplasia 7:49-66.
52. WAF1 cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 273:10696-10701.
53. Pagliuca, A., P. Gallo, and L. Lania. 2000. Differential role for Sp1/Sp3 transcription factors in the regulation of the promoter activity of multiple cyclin-dependent kinase inhibitor genes. J. Cell Biochem. 76:360-367.
54. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222-225.
55. Reed, W., V. A. Florems, R. Holm, E. Hannisdal, and J. M. Nesland. 1999. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch. 435:116-124.
56. Rodriguez-Boulan, E., and W. J. Nelson. 1989. Morphogenesis of the polarized epithelial cell phenotype. Science 245:718-725.
57. Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, J. M. Kotchen, and J. Ockene. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
58. Said, T. K., R. C. Moraes, U. Singh, F. S. Kittrell, and D. Medina. 2001. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ. 12:285-295.
59. Schuler, G. D., M. S. Boguski, E. A. Stewart, L. D. Stein, G. Gyapay, K. Rice, R. E. White, P. Rodriguez-Tome, A. Aggarwal, E. Bajorek, S. Bentolila, B. B. Birren, A. Butler, A. B. Castle, N. Chiannilkulchai, A. Chu, C. Clee, S. Cowles, P. J. Day, T. Dibling, N. Drouot, I. Dunham, S. Duprat, C. East, T. J. Hudson, et al. 1996. A gene map of the human genome. Science 274:540-546.
60. Shiozawa, T., H. C. Shih, T. Miyamoto, Y. Z. Feng, J. Uchikawa, K. Itoh, and I. Konishi. 2003. Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. J. Clin. Endocrinol. Metab. 88:871-878.
61. Sitruk-Ware, R., and G. Plu-Bureau. 1999. Progestins and cancer. Gynecol. Endocrinol. 13(Suppl. 4):3-9.
62. Sivaraman, L., and D. Medina. 2002. Hormone-induced protection against breast cancer. J. Mammary Gland Biol. Neoplasia 7:77-92.
63. Slater, E. P., A. C. Cato, M. Karin, J. D. Baxter, and M. Beato. 1988. Progesterone induction of metallothionein-IIA gene expression. Mol. Endocrinol. 2:485-491.
64. Smith, C. L., and B. W. O'Malley. 2004. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25:45-71.
65. Smith, C. L., S. A. Onate, M. J. Tsai, and B. W. O'Malley. 1996. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. USA 93:8884-8888.
66. WAF1/. Nature 389:187-190.
67. Sommers, C. L., S. W. Byers, E. W. Thompson, J. A. Torri, and E. P. Gelmann. 1994. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res. Treat. 31:325-335.
68. Stahlberg, C., A. T. Pederson, E. Lynge, and B. Ottesen. 2003. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet. Gynecol. Scand. 82:335-344.
69. INKc in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol. Cell. Biol. 20:2581-2591.
70. T'Ang, A., J. M. Varley, S. Chakraborty, A. L. Murphree, and Y. K. Fung. 1988. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242:263-266.
71. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
72. Zheng, L., L. A. Annab, C. A. Afshari, W. H. Lee, and T. G. Boyer. 2001. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl. Acad. Sci. USA 98:9587-9592.